
Global Anti-obesity Medicine Industry Growth and Trends Forecast to 2031
Description
Summary
According to APO Research, The global Anti-obesity Medicine market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.
North American market for Anti-obesity Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Asia-Pacific market for Anti-obesity Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Europe market for Anti-obesity Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
The major global companies of Anti-obesity Medicine include Eisai, Novo Nordisk, Merck, Roche, Pfizer, GlaxoSmithKline, Vivus, Orexigen Therapeutics and Boehringer Ingelheim, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Anti-obesity Medicine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-obesity Medicine.
The Anti-obesity Medicine market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Anti-obesity Medicine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, gross margin by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Anti-obesity Medicine Segment by Company
Eisai
Novo Nordisk
Merck
Roche
Pfizer
GlaxoSmithKline
Vivus
Orexigen Therapeutics
Boehringer Ingelheim
Arena Pharmaceuticals
Amylin Pharmaceuticals
Alizyme
Anti-obesity Medicine Segment by Type
Prescription Drugs
OTC Drugs
Anti-obesity Medicine Segment by Application
Men
Women
Anti-obesity Medicine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-obesity Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-obesity Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-obesity Medicine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2020-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Anti-obesity Medicine companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
According to APO Research, The global Anti-obesity Medicine market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.
North American market for Anti-obesity Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Asia-Pacific market for Anti-obesity Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Europe market for Anti-obesity Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
The major global companies of Anti-obesity Medicine include Eisai, Novo Nordisk, Merck, Roche, Pfizer, GlaxoSmithKline, Vivus, Orexigen Therapeutics and Boehringer Ingelheim, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Anti-obesity Medicine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-obesity Medicine.
The Anti-obesity Medicine market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Anti-obesity Medicine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, gross margin by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Anti-obesity Medicine Segment by Company
Eisai
Novo Nordisk
Merck
Roche
Pfizer
GlaxoSmithKline
Vivus
Orexigen Therapeutics
Boehringer Ingelheim
Arena Pharmaceuticals
Amylin Pharmaceuticals
Alizyme
Anti-obesity Medicine Segment by Type
Prescription Drugs
OTC Drugs
Anti-obesity Medicine Segment by Application
Men
Women
Anti-obesity Medicine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-obesity Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-obesity Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-obesity Medicine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2020-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Anti-obesity Medicine companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
Table of Contents
104 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Anti-obesity Medicine Market Size Overview by Region 2020 VS 2024 VS 2031
- 1.4 Global Anti-obesity Medicine Market Size by Region (2020-2031)
- 1.4.1 Global Anti-obesity Medicine Market Size by Region (2020-2025)
- 1.4.2 Global Anti-obesity Medicine Market Size by Region (2026-2031)
- 1.5 Key Regions Anti-obesity Medicine Market Size (2020-2031)
- 1.5.1 North America Anti-obesity Medicine Market Size Growth Rate (2020-2031)
- 1.5.2 Europe Anti-obesity Medicine Market Size Growth Rate (2020-2031)
- 1.5.3 Asia-Pacific Anti-obesity Medicine Market Size Growth Rate (2020-2031)
- 1.5.4 South America Anti-obesity Medicine Market Size Growth Rate (2020-2031)
- 1.5.5 Middle East & Africa Anti-obesity Medicine Market Size Growth Rate (2020-2031)
- 2 Anti-obesity Medicine Market by Type
- 2.1 Type Introduction
- 2.1.1 Prescription Drugs
- 2.1.2 OTC Drugs
- 2.2 Global Anti-obesity Medicine Market Size by Type
- 2.2.1 Global Anti-obesity Medicine Market Size Overview by Type (2020-2031)
- 2.2.2 Global Anti-obesity Medicine Historic Market Size Review by Type (2020-2025)
- 2.2.3 Global Anti-obesity Medicine Market Size Forecasted by Type (2026-2031)
- 2.3 Global Anti-obesity Medicine Market Size by Regions
- 2.3.1 North America Anti-obesity Medicine Market Size Breakdown by Type (2020-2025)
- 2.3.2 Europe Anti-obesity Medicine Market Size Breakdown by Type (2020-2025)
- 2.3.3 Asia-Pacific Anti-obesity Medicine Market Size Breakdown by Type (2020-2025)
- 2.3.4 South America Anti-obesity Medicine Market Size Breakdown by Type (2020-2025)
- 2.3.5 Middle East and Africa Anti-obesity Medicine Market Size Breakdown by Type (2020-2025)
- 3 Anti-obesity Medicine Market by Application
- 3.1 Type Introduction
- 3.1.1 Men
- 3.1.2 Women
- 3.2 Global Anti-obesity Medicine Market Size by Application
- 3.2.1 Global Anti-obesity Medicine Market Size Overview by Application (2020-2031)
- 3.2.2 Global Anti-obesity Medicine Historic Market Size Review by Application (2020-2025)
- 3.2.3 Global Anti-obesity Medicine Market Size Forecasted by Application (2026-2031)
- 3.3 Global Anti-obesity Medicine Market Size by Regions
- 3.3.1 North America Anti-obesity Medicine Market Size Breakdown by Application (2020-2025)
- 3.3.2 Europe Anti-obesity Medicine Market Size Breakdown by Application (2020-2025)
- 3.3.3 Asia-Pacific Anti-obesity Medicine Market Size Breakdown by Application (2020-2025)
- 3.3.4 South America Anti-obesity Medicine Market Size Breakdown by Application (2020-2025)
- 3.3.5 Middle East and Africa Anti-obesity Medicine Market Size Breakdown by Application (2020-2025)
- 4 Global Market Dynamics
- 4.1 Anti-obesity Medicine Industry Trends
- 4.2 Anti-obesity Medicine Industry Drivers
- 4.3 Anti-obesity Medicine Industry Opportunities and Challenges
- 4.4 Anti-obesity Medicine Industry Restraints
- 5 Competitive Insights by Company
- 5.1 Global Top Players by Anti-obesity Medicine Revenue (2020-2025)
- 5.2 Global Anti-obesity Medicine Industry Company Ranking, 2023 VS 2024 VS 2025
- 5.3 Global Anti-obesity Medicine Key Company Headquarters & Area Served
- 5.4 Global Anti-obesity Medicine Company, Product Type & Application
- 5.5 Global Anti-obesity Medicine Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Anti-obesity Medicine Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Anti-obesity Medicine Players Market Share by Revenue in 2024
- 5.6.3 2024 Anti-obesity Medicine Tier 1, Tier 2, and Tier 3
- 6 Company Profiles
- 6.1 Eisai
- 6.1.1 Eisai Comapny Information
- 6.1.2 Eisai Business Overview
- 6.1.3 Eisai Anti-obesity Medicine Revenue, Global Share and Gross Margin (2020-2025)
- 6.1.4 Eisai Anti-obesity Medicine Product Portfolio
- 6.1.5 Eisai Recent Developments
- 6.2 Novo Nordisk
- 6.2.1 Novo Nordisk Comapny Information
- 6.2.2 Novo Nordisk Business Overview
- 6.2.3 Novo Nordisk Anti-obesity Medicine Revenue, Global Share and Gross Margin (2020-2025)
- 6.2.4 Novo Nordisk Anti-obesity Medicine Product Portfolio
- 6.2.5 Novo Nordisk Recent Developments
- 6.3 Merck
- 6.3.1 Merck Comapny Information
- 6.3.2 Merck Business Overview
- 6.3.3 Merck Anti-obesity Medicine Revenue, Global Share and Gross Margin (2020-2025)
- 6.3.4 Merck Anti-obesity Medicine Product Portfolio
- 6.3.5 Merck Recent Developments
- 6.4 Roche
- 6.4.1 Roche Comapny Information
- 6.4.2 Roche Business Overview
- 6.4.3 Roche Anti-obesity Medicine Revenue, Global Share and Gross Margin (2020-2025)
- 6.4.4 Roche Anti-obesity Medicine Product Portfolio
- 6.4.5 Roche Recent Developments
- 6.5 Pfizer
- 6.5.1 Pfizer Comapny Information
- 6.5.2 Pfizer Business Overview
- 6.5.3 Pfizer Anti-obesity Medicine Revenue, Global Share and Gross Margin (2020-2025)
- 6.5.4 Pfizer Anti-obesity Medicine Product Portfolio
- 6.5.5 Pfizer Recent Developments
- 6.6 GlaxoSmithKline
- 6.6.1 GlaxoSmithKline Comapny Information
- 6.6.2 GlaxoSmithKline Business Overview
- 6.6.3 GlaxoSmithKline Anti-obesity Medicine Revenue, Global Share and Gross Margin (2020-2025)
- 6.6.4 GlaxoSmithKline Anti-obesity Medicine Product Portfolio
- 6.6.5 GlaxoSmithKline Recent Developments
- 6.7 Vivus
- 6.7.1 Vivus Comapny Information
- 6.7.2 Vivus Business Overview
- 6.7.3 Vivus Anti-obesity Medicine Revenue, Global Share and Gross Margin (2020-2025)
- 6.7.4 Vivus Anti-obesity Medicine Product Portfolio
- 6.7.5 Vivus Recent Developments
- 6.8 Orexigen Therapeutics
- 6.8.1 Orexigen Therapeutics Comapny Information
- 6.8.2 Orexigen Therapeutics Business Overview
- 6.8.3 Orexigen Therapeutics Anti-obesity Medicine Revenue, Global Share and Gross Margin (2020-2025)
- 6.8.4 Orexigen Therapeutics Anti-obesity Medicine Product Portfolio
- 6.8.5 Orexigen Therapeutics Recent Developments
- 6.9 Boehringer Ingelheim
- 6.9.1 Boehringer Ingelheim Comapny Information
- 6.9.2 Boehringer Ingelheim Business Overview
- 6.9.3 Boehringer Ingelheim Anti-obesity Medicine Revenue, Global Share and Gross Margin (2020-2025)
- 6.9.4 Boehringer Ingelheim Anti-obesity Medicine Product Portfolio
- 6.9.5 Boehringer Ingelheim Recent Developments
- 6.10 Arena Pharmaceuticals
- 6.10.1 Arena Pharmaceuticals Comapny Information
- 6.10.2 Arena Pharmaceuticals Business Overview
- 6.10.3 Arena Pharmaceuticals Anti-obesity Medicine Revenue, Global Share and Gross Margin (2020-2025)
- 6.10.4 Arena Pharmaceuticals Anti-obesity Medicine Product Portfolio
- 6.10.5 Arena Pharmaceuticals Recent Developments
- 6.11 Amylin Pharmaceuticals
- 6.11.1 Amylin Pharmaceuticals Comapny Information
- 6.11.2 Amylin Pharmaceuticals Business Overview
- 6.11.3 Amylin Pharmaceuticals Anti-obesity Medicine Revenue, Global Share and Gross Margin (2020-2025)
- 6.11.4 Amylin Pharmaceuticals Anti-obesity Medicine Product Portfolio
- 6.11.5 Amylin Pharmaceuticals Recent Developments
- 6.12 Alizyme
- 6.12.1 Alizyme Comapny Information
- 6.12.2 Alizyme Business Overview
- 6.12.3 Alizyme Anti-obesity Medicine Revenue, Global Share and Gross Margin (2020-2025)
- 6.12.4 Alizyme Anti-obesity Medicine Product Portfolio
- 6.12.5 Alizyme Recent Developments
- 7 North America
- 7.1 North America Anti-obesity Medicine Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 7.2 North America Anti-obesity Medicine Market Size by Country (2020-2025)
- 7.3 North America Anti-obesity Medicine Market Size Forecast by Country (2026-2031)
- 8 Europe
- 8.1 Europe Anti-obesity Medicine Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 8.2 Europe Anti-obesity Medicine Market Size by Country (2020-2025)
- 8.3 Europe Anti-obesity Medicine Market Size Forecast by Country (2026-2031)
- 9 Asia-Pacific
- 9.1 Asia-Pacific Anti-obesity Medicine Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 9.2 Asia-Pacific Anti-obesity Medicine Market Size by Country (2020-2025)
- 9.3 Asia-Pacific Anti-obesity Medicine Market Size Forecast by Country (2026-2031)
- 10 South America
- 10.1 South America Anti-obesity Medicine Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 10.2 South America Anti-obesity Medicine Market Size by Country (2020-2025)
- 10.3 South America Anti-obesity Medicine Market Size Forecast by Country (2026-2031)
- 11 Middle East & Africa
- 11.1 Middle East & Africa Anti-obesity Medicine Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 11.2 Middle East & Africa Anti-obesity Medicine Market Size by Country (2020-2025)
- 11.3 Middle East & Africa Anti-obesity Medicine Market Size Forecast by Country (2026-2031)
- 12 Concluding Insights
- 13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.